Search research articles
Contact Us
Filters
Showing results (101-110 of 123) with videos related to
Page
of 13
Sort By:
Neurogastroenterology and Motility
|
September 11, 2009
The effect of esomeprazole 20 mg twice daily on acoustic and perception parameters of the voice in laryngopharyngeal reflux
R Fass, N Noelck, M R Willis, et al.
Archives of Internal Medicine
|
October 20, 1999
Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease
R Fass, J J Ofman, I M Gralnek, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus
|
September 21, 2006
Correlation of gastroesophageal reflux disease symptoms characteristics with long-segment Barrett's esophagus
R Dickman, J L Kim, L Camargo, et al.
Gastroenterology
|
July 3, 1998
The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain
R Fass, M B Fennerty, J J Ofman, et al.
Alimentary Pharmacology & Therapeutics
|
January 19, 2007
Assessment of dietary nutrients that influence perception of intra-oesophageal acid reflux events in patients with gastro-oesophageal reflux disease
M Shapiro, C Green, J M Bautista, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus
|
September 21, 2006
Esophageal acid exposure at pH < or = 2 is more common in Barrett's esophagus patients and is associated with oxidative stress
K Dvorak, R Fass, R Dekel, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 15, 1991
Suppression of the immune response to immunotoxins with anti-CD4 monoclonal antibodies
F S Jin, R J Youle, V G Johnson, et al.
Alimentary Pharmacology & Therapeutics
|
April 28, 2009
Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease
R Fass, W D Chey, S F Zakko, et al.
Alimentary Pharmacology & Therapeutics
|
May 3, 2000
Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor
R Fass, R E Sampliner, I B Malagon, et al.
Alimentary Pharmacology & Therapeutics
|
April 12, 2000
Clinical and fiscal impact of lansoprazole intolerance in veterans with gastro-oesophageal reflux disease
L B Gerson, B N Hatton, R Ryono, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 123) with videos related to
Sort By:
Page
of 13
Neurogastroenterology and Motility
|
September 11, 2009
The effect of esomeprazole 20 mg twice daily on acoustic and perception parameters of the voice in laryngopharyngeal reflux
R Fass, N Noelck, M R Willis, et al.
Archives of Internal Medicine
|
October 20, 1999
Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease
R Fass, J J Ofman, I M Gralnek, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus
|
September 21, 2006
Correlation of gastroesophageal reflux disease symptoms characteristics with long-segment Barrett's esophagus
R Dickman, J L Kim, L Camargo, et al.
Gastroenterology
|
July 3, 1998
The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain
R Fass, M B Fennerty, J J Ofman, et al.
Alimentary Pharmacology & Therapeutics
|
January 19, 2007
Assessment of dietary nutrients that influence perception of intra-oesophageal acid reflux events in patients with gastro-oesophageal reflux disease
M Shapiro, C Green, J M Bautista, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus
|
September 21, 2006
Esophageal acid exposure at pH < or = 2 is more common in Barrett's esophagus patients and is associated with oxidative stress
K Dvorak, R Fass, R Dekel, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 15, 1991
Suppression of the immune response to immunotoxins with anti-CD4 monoclonal antibodies
F S Jin, R J Youle, V G Johnson, et al.
Alimentary Pharmacology & Therapeutics
|
April 28, 2009
Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease
R Fass, W D Chey, S F Zakko, et al.
Alimentary Pharmacology & Therapeutics
|
May 3, 2000
Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor
R Fass, R E Sampliner, I B Malagon, et al.
Alimentary Pharmacology & Therapeutics
|
April 12, 2000
Clinical and fiscal impact of lansoprazole intolerance in veterans with gastro-oesophageal reflux disease
L B Gerson, B N Hatton, R Ryono, et al.
Page
of 13